Helpful Information for Physicians

Dosage:

For Severe Conditions

• Rheumatic pain – 3 capsules per day (morning, midday and evening with meals)
• Gout – 4 capsules per day (morning, midday and evening with meals)

Mild Discomfort and Continuation After Treatment

• 1-2 capsules per day

Precautions:
Not to be used in pregnancy or by persons with heart disease unless under medical supervision. Not suitable for children under the age of 12.

Clinical Support:
A pilot longitudinal biomedical study on the use of phthalides for the relief of rheumatic pain demonstrated significant pain relief over 12 weeks of treatment. After cessation of treatment the volunteers returned to the study on their own volition and the reduction in pain level was achieved at a greater rate than at the beginning of the study. Based on these results a larger clinicall study was undertaken on 70 volunteers over 3 weeks of treatment using an improved preparation, 3nB Celery Seed Extract.

The volunteers were clinically assessed and categorized accordingly to the severity of their rheumatic illness (morning stiffness, night pain and day pain). Descriptive pain intensity was based on self assessment by the volunteers, as well as self assessment using the vertical analogue scale for the degree of pain and well being. These self-assessments were also compared with quantitative clinical pain measurement using the McGill Pain Rating (PRI). All descriptor and quantitative analysis demonstrated statistically significant reductions in pain and an increase in well being. This also applied to those volunteers taking maintenance drugs for their rheumatic illness.

There was a significant statistical movement in the descriptor analysis from the severe to the less severe categories, with corresponding movement from constant to momentary pain with a decrease in pain intensity. Similarly the quantitative analysis demonstrated a statistically significant decrease in the PRI (19% - 51%), vertical analogue Pain Scale (12% - 45%), an increase in well being (7% - 34%) and an improvement in mobility (1% - 49%).